Global Tubulin Inhibitors for Breast Cancer Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Eribulin
  • 1.4.3 Ixabepilone
  • 1.4.4 Docetaxel
  • 1.4.5 Trastuzumab Emtansine
  • 1.4.6 Utidelone
  • 1.4.7 Paclitaxel
  • 1.4.8 Liposome Paclitaxel
  • 1.4.9 Protein-bound Paclitaxel
• 1.5 Market by Application
  • 1.5.1 Global Tubulin Inhibitors for Breast Cancer Market Share by Application (2014-2025)
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Drug Center
  • 1.5.5 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Tubulin Inhibitors for Breast Cancer Market Size
• 2.2 Tubulin Inhibitors for Breast Cancer Growth Trends by Regions
  • 2.2.1 Tubulin Inhibitors for Breast Cancer Market Size by Regions (2014-2025)
  • 2.2.2 Tubulin Inhibitors for Breast Cancer Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Tubulin Inhibitors for Breast Cancer Market Size by by Players
  • 3.1.1 Global Tubulin Inhibitors for Breast Cancer Revenue by by Players (2014-2019)
  • 3.1.2 Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Tubulin Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI)
• 3.2 Tubulin Inhibitors for Breast Cancer Key Players Head office and Area Served
• 3.3 Key Players Tubulin Inhibitors for Breast Cancer Product/Solution/Service
• 3.4 Date of Enter into Tubulin Inhibitors for Breast Cancer Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Tubulin Inhibitors for Breast Cancer Market Size by Type (2014-2019)
• 4.2 Global Tubulin Inhibitors for Breast Cancer Market Size by Application (2014-2019)

5 United States

• 5.1 United States Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
• 5.2 Tubulin Inhibitors for Breast Cancer Key Players in United States
• 5.3 United States Tubulin Inhibitors for Breast Cancer Market Size by Type
• 5.4 United States Tubulin Inhibitors for Breast Cancer Market Size by Application

6 Europe

• 6.1 Europe Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
• 6.2 Tubulin Inhibitors for Breast Cancer Key Players in Europe
• 6.3 Europe Tubulin Inhibitors for Breast Cancer Market Size by Type
• 6.4 Europe Tubulin Inhibitors for Breast Cancer Market Size by Application

7 China

• 7.1 China Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
• 7.2 Tubulin Inhibitors for Breast Cancer Key Players in China
• 7.3 China Tubulin Inhibitors for Breast Cancer Market Size by Type
• 7.4 China Tubulin Inhibitors for Breast Cancer Market Size by Application

8 Japan

• 8.1 Japan Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
• 8.2 Tubulin Inhibitors for Breast Cancer Key Players in Japan
• 8.3 Japan Tubulin Inhibitors for Breast Cancer Market Size by Type
• 8.4 Japan Tubulin Inhibitors for Breast Cancer Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
• 9.2 Tubulin Inhibitors for Breast Cancer Key Players in Southeast Asia
• 9.3 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size by Type
• 9.4 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size by Application

10 India

• 10.1 India Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
• 10.2 Tubulin Inhibitors for Breast Cancer Key Players in India
• 10.3 India Tubulin Inhibitors for Breast Cancer Market Size by Type
• 10.4 India Tubulin Inhibitors for Breast Cancer Market Size by Application

11 Central & South America

• 11.1 Central & South America Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
• 11.2 Tubulin Inhibitors for Breast Cancer Key Players in Central & South America
• 11.3 Central & South America Tubulin Inhibitors for Breast Cancer Market Size by Type
• 11.4 Central & South America Tubulin Inhibitors for Breast Cancer Market Size by Application

12 International Players Profiles

• 12.1 Eisai
  • 12.1.1 Eisai Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.1.4 Eisai Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.1.5 Eisai Recent Development
• 12.2 Bristol-Myers Squibb
  • 12.2.1 Bristol-Myers Squibb Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.2.4 Bristol-Myers Squibb Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.2.5 Bristol-Myers Squibb Recent Development
• 12.3 Otsuka Pharmaceutical
  • 12.3.1 Otsuka Pharmaceutical Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.3.4 Otsuka Pharmaceutical Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.3.5 Otsuka Pharmaceutical Recent Development
• 12.4 Hengrui Medicine
  • 12.4.1 Hengrui Medicine Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.4.4 Hengrui Medicine Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.4.5 Hengrui Medicine Recent Development
• 12.5 Sanofi
  • 12.5.1 Sanofi Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.5.4 Sanofi Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.5.5 Sanofi Recent Development
• 12.6 Qilu Pharma
  • 12.6.1 Qilu Pharma Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.6.4 Qilu Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.6.5 Qilu Pharma Recent Development
• 12.7 Shenzhen Main Luck Pharma
  • 12.7.1 Shenzhen Main Luck Pharma Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.7.4 Shenzhen Main Luck Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.7.5 Shenzhen Main Luck Pharma Recent Development
• 12.8 Jiangsu Aosaikang Pharma
  • 12.8.1 Jiangsu Aosaikang Pharma Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.8.4 Jiangsu Aosaikang Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.8.5 Jiangsu Aosaikang Pharma Recent Development
• 12.9 Genentech
  • 12.9.1 Genentech Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.9.4 Genentech Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.9.5 Genentech Recent Development
• 12.10 Beijing Biostar Technologies
  • 12.10.1 Beijing Biostar Technologies Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Tubulin Inhibitors for Breast Cancer Introduction
  • 12.10.4 Beijing Biostar Technologies Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
  • 12.10.5 Beijing Biostar Technologies Recent Development
• 12.11 Celgene Corporation
• 12.12 Hospira
• 12.13 Biological E.
• 12.14 Taj Accura
• 12.15 Khandelwal Laboratories
• 12.16 Luye Pharma
• 12.17 Beijing Youcare
• 12.18 Beijing Union
• 12.19 Haiyao
• 12.20 Chuntch
• 12.21 CSPC Pharmaceutical
• 12.22 Aosaikang Pharm

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer